Latest news with #Plasma
Yahoo
3 days ago
- Business
- Yahoo
HAE Q1 Earnings Call: Revenue Misses Expectations, Margin Expansion and Product Focus Highlighted
Blood products company Haemonetics (NYSE:HAE). fell short of the market's revenue expectations in Q1 CY2025, with sales falling 3.7% year on year to $330.6 million. Its non-GAAP EPS of $1.24 per share was 1.6% above analysts' consensus estimates. Is now the time to buy HAE? Find out in our full research report (it's free). Revenue: $330.6 million (3.7% year-on-year decline) Adjusted EPS: $1.24 vs analyst estimates of $1.22 (1.6% beat) Adjusted EPS guidance for the upcoming financial year 2026 is $4.85 at the midpoint, missing analyst estimates by 1.2% Operating Margin: 21.6%, up from 8.7% in the same quarter last year Organic Revenue was flat year on year (10.2% in the same quarter last year) Market Capitalization: $3.35 billion Haemonetics reported first quarter results marked by revenue declines, but management emphasized the impact of its evolving product portfolio and operational changes. CEO Chris Simon attributed performance to strong growth in the Hospital segment, led by technologies such as TEG and VASCADE, and highlighted the successful divestiture of the Whole Blood business. He noted that expanded adoption of next-generation products, particularly in Plasma technology, contributed to margin improvement. Simon also referenced the company's ongoing focus on higher-margin product categories and operational discipline as factors that contributed to the quarter's profitability, stating, 'Our industry-leading NexSys, TEG and VASCADE technologies continue to propel our growth in attractive markets.' Looking forward, Haemonetics' guidance reflects a cautious outlook as the company anticipates ongoing headwinds from portfolio transitions and external market factors. Management expects organic growth to be driven mainly by increased utilization and share gains in Plasma and Hospital technologies, while acknowledging a potential rebound in collection volumes later in the year. CFO James D'Arecca warned that reported revenue is expected to decline due to the completed Whole Blood divestiture and continued impacts from the CSL contract transition, but emphasized that gross margin expansion and disciplined cost management should support profitability. D'Arecca stated, 'We expect adjusted operating margin to improve by 200 to 300 basis points... supported by continued gains in adjusted gross margin.' Management traced the quarter's performance to a mix of product portfolio shifts, margin expansion, and strategic focus on high-growth segments, while also pointing to contract transitions and market-specific headwinds. Hospital segment momentum: Growth was led by Hospital products, including Blood Management Technologies and Interventional Technologies, with double-digit increases in both franchises. The TEG viscoelastic testing platform saw accelerated adoption, particularly with the launch of the HN cartridge, driving new account openings and transitions from older models. Vascular Closure advances: The VASCADE MVP and MVP XL devices in the Interventional Technologies franchise delivered over 25% growth due to new account openings and increased U.S. and Japanese utilization. However, legacy VASCADE products for coronary and peripheral procedures saw slower growth, which management aims to address through focused sales efforts. Plasma technology adoption: Plasma revenue was buoyed by the adoption of next-generation technologies like Persona and Express Plus, resulting in share gains and increased margins. Management highlighted new multi-year agreements with major collectors, which are expected to continue contributing to growth. Portfolio transformation and divestitures: The completed divestiture of the Whole Blood business enabled resource reallocation to higher-growth, higher-margin areas. This shift contributed to the significant improvement in overall operating margins and supported disciplined capital allocation, including share repurchases. Leadership and organizational changes: The promotions of Roy Galvin to Chief Commercial Officer and Frank Chan to Chief Operating Officer were cited as key steps to strengthen commercial execution and operations, particularly in supporting the Hospital business's long-term growth plans. Haemonetics expects near-term revenue to be shaped by portfolio transitions, while focusing on margin gains and product adoption to drive future growth and profitability. Product utilization and share gains: Management anticipates that growth will be led by increased utilization of existing devices, especially in Plasma and Vascular Closure, supported by recent extended contracts with major plasma collectors. New hospital product launches and technology conversions are expected to offset headwinds in legacy product lines. Margin expansion and cost discipline: The company projects further improvement in operating margins through portfolio mix shifts towards higher-margin products and ongoing cost control measures. Approximately $30 million in savings are expected over the next two years through regional alignment and operational efficiencies. External risks and market headwinds: Haemonetics identified tariff exposure, timing of contract transitions, and softness in the Chinese market as areas of uncertainty. While management expects U.S. and European momentum to offset challenges, external factors could impact both revenue progression and profitability in the coming quarters. In the next few quarters, the StockStory team will monitor (1) the pace of technology adoption and utilization in the Plasma and Hospital segments, (2) execution against targeted improvements in Vascular Closure—especially legacy product turnaround efforts, and (3) margin performance as cost savings and portfolio transformation initiatives take hold. Progress on regulatory approvals and new product launches will also be important milestones. Haemonetics currently trades at a forward P/E ratio of 14.2×. Should you double down or take your chips? The answer lies in our full research report (it's free). The market surged in 2024 and reached record highs after Donald Trump's presidential victory in November, but questions about new economic policies are adding much uncertainty for 2025. While the crowd speculates what might happen next, we're homing in on the companies that can succeed regardless of the political or macroeconomic environment. Put yourself in the driver's seat and build a durable portfolio by checking out our Top 5 Growth Stocks for this month. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025). Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,754% five-year return). Find your next big winner with StockStory today. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
17-05-2025
- Health
- Business Wire
Fujirebio Receives Marketing Clearance for Lumipulse ® G pTau 217/ β-Amyloid 1-42 Plasma Ratio In-vitro Diagnostic Test as an Aid to Identify Patients With Amyloid Pathology Associated With Alzheimer's Disease
MALVERN, Pa., & TOKYO--(BUSINESS WIRE)--Fujirebio today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for the company's Lumipulse ® G pTau 217/β-Amyloid 1-42 Plasma Ratio in-vitro diagnostic (IVD) test for the assessment of amyloid pathology in patients being evaluated for Alzheimer's disease and other causes of cognitive decline. The test, which was granted Breakthrough Device Designation by the FDA, is the first FDA cleared blood-based IVD test in the U.S. to aid to identify patients with amyloid pathology associated with Alzheimer's Disease (AD). Alzheimer's disease currently affects an estimated 7.2 million Americans, a number projected to rise to nearly 14 million by 2060. 1 It is a leading cause of disability and death. AD develops over many years, long before symptoms are evident, but the lack of accessible, minimally invasive diagnostics results in many patients remaining undiagnosed until the disease is well advanced, when few effective interventions remain. The Lumipulse G pTau 217/β-Amyloid 1-42 Plasma Ratio test is an accurate, minimally invasive, accessible measurement of pTau 217 and β-Amyloid 1-42 concentrations in plasma as a proxy for the presence of β-Amyloid plaque pathology in the brain. It is intended for use in adult patients aged 50 years and older presenting at a specialized care setting with signs and symptoms of cognitive decline. In a clinical study population of 499 patients, which closely mirrored the US demographics, and when applying a dual cut point, the test demonstrated a positive predicate value (PPV) of 92%, a negative predicate value (NPV) of 97% with only 20% patients who are uncertain to have amyloid pathology, thus requiring further testing. The Lumipulse pTau 217/ β-Amyloid 1-42 Plasma Ratio test uses Fujirebio's fully automated LUMIPULSE ® G1200 instrument system, which is widely available in clinical laboratories throughout the U.S. The new ratio test complements the Lumipulse G β-Amyloid Ratio (1-42/1-40), authorized by the FDA for use in CSF in May 2022. 'The lack of effective, accessible and minimally invasive diagnostics for AD contributes to its late diagnosis and inadequate treatment,' says Monte Wiltse, President and CEO at Fujirebio Diagnostics, Inc. 'The Lumipulse G pTau 217/ β-Amyloid 1-42 Plasma Ratio test will go a long way to assist physicians and patients to obtain an AD diagnosis in early stages of the disease, when interventions are more effective. As part of our worldwide commitment to improve the diagnosis and treatment of AD, Fujirebio is developing additional assays, which will increase the availability of diagnostic tools and expand the foundation for early, more effective treatment.' About Fujirebio Fujirebio, a member of H.U. Group Holdings Inc., is a global leader in the field of high-quality in vitro diagnostics (IVD) testing. It has more than 50 years' accumulated experience in the conception, development, production and worldwide commercialization of robust IVD products. Fujirebio was the first company to develop and market CSF biomarkers under the Innogenetics brand over 25 years ago. Fujirebio offers a comprehensive line-up of manual and fully automated assays for neurological diseases and consistently partners with organizations and clinical experts across the world to develop new pathways for earlier, easier and more complete neurodegenerative diagnostic tools. More information can be found at About Fujirebio Diagnostics, Inc. Fujirebio Diagnostics, Inc., a wholly-owned subsidiary of Fujirebio Holdings, Inc., is the premier cancer diagnostics company and the industry leader in cancer biomarker assays. The company pioneered and introduced the CA125 test, the first FDA-approved ovarian cancer biomarker, over 25 years ago. Fujirebio Diagnostics specializes in the clinical development, manufacturing and commercialization of in-vitro diagnostic products for the management of human disease states, with an emphasis in oncology. For more information about Fujirebio Diagnostics, please call +1 610-240-3800 or visit us at Reference
Arabian Post
04-05-2025
- Arabian Post
KDE Ends Long-Term Support for Plasma Desktop
KDE has officially ceased the long-term support releases of its Plasma desktop environment, marking a significant shift in its development strategy. The decision, confirmed during a developer sprint in Graz, Austria, reflects a move towards more frequent and uniformly supported releases, aligning with the project's evolving priorities and resource allocation. The discontinuation of LTS versions stems from multiple factors. Developers cited inconsistent expectations from users, challenges in maintaining older codebases, and the complexities of backporting fixes without introducing new issues. Nate Graham, a prominent KDE contributor, noted that LTS releases often involved backporting fixes 'usually without even testing them,' leading to potential stability concerns. Instead of LTS versions, KDE plans to extend the support period for regular Plasma releases. This approach includes adding an extra bug-fix release, increasing the number from five to six per cycle. The aim is to provide a more stable and reliable experience for users without the overhead of maintaining separate LTS branches. KDE is considering reducing the number of Plasma releases per year from three to two. This change would allow better alignment with major Linux distributions like Kubuntu and Fedora, facilitating smoother integration and testing processes. The decision also addresses the issue of users reporting bugs from LTS distributions to KDE developers, even when those issues stemmed from the distributions' packaging. By focusing on a unified release strategy, KDE aims to streamline support and development efforts.
Yahoo
22-04-2025
- Business
- Yahoo
Matter Labs, ZKsync Developer, Sued for Alleged Intellectual Property Theft
Matter Labs, the company behind layer-2 blockchain ZKSync, has been sued by BANKEX, a defunct digital asset banking platform, for intellectual property theft. According to a complaint filed Mar. 19 with the New York State Supreme Court, former BANKEX employees Alexandr Vlasov and Petr Korolev allegedly stole the company's technology to start Matter Labs, which received over $450 million in venture capital funding and has become a major player in the blockchain industry. The complaint, which names BANKEX CEO Igor Khmel and the BANKEX Foundation as plaintiffs, alleged BANKEX was approached by Ethereum co-founder Vitalik Buterin in 2017 to build operational software for "Plasma," a technology that was seen at the time as a way to make Ethereum cheaper to use. According to the complaint, Alexandr Vlasov and Petr Korolev were BANKEX employees at the time and were tasked by BANKEX CEO Igor Khemel with completing the Plasma project. The complaint alleged that Vlasov and Korolev instead secretly developed 'a competing company, Matter Labs, through which they intended to appropriate the blockchain technology of BANKEX for their own use and benefit and to compete with BANKEX.' In addition, the complaint claimed that the two developers were secretly transferring 'BANKEX's technology to Matter Labs and covertly developed and stored operational code bases' using the company's resources and funding. Vlasov is currently the head of R&D at Matter Labs, and Korolev is the founder of blockchain security firm OXORIO, according to their LinkedIn profiles. Matter Labs co-founder Alex Gluchowski, crypto-native investment fund Dragonfly, and Chris Burniske, a partner at Placeholder Capital and a former co-director at Matter Labs, are also being sued for their alleged involvement and knowledge of the theft. 'We believe these claims are entirely without merit," a spokesperson at Matter Labs told CoinDesk in an emailed statement. "The thrust of the complaint is that Matter Labs built ZKsync on top of code that was originally developed at Bankex. This is categorically false. ZKsync is original technology that is not based on or derived from any code developed by Bankex. We stand by the integrity of our work and look forward to addressing these baseless allegations in court once we are served." Dragonfly, Burniske and Korolev did not respond to multiple requests for comment. BANKEX lawyer Clayton Mahaffey told CoinDesk in a statement that the firm "prefers not to comment further on the case at this time, other than to reiterate its belief that the allegations in the complaint are well founded and that it looks forward to its day in court."
Al Mesryoon
21-04-2025
- Health
- Al Mesryoon
Best Hair Transplant in Turkey with Capilclinic's Award-Winning Experts
Discover the Best Hair Transplant Solution in Turkey with Capilclinic Let's not sugarcoat it—when it comes to your hair, you want the best hair transplant in Turkey, not just a 'good deal.' You want a result that looks natural. You want to feel confident again when you look in the mirror. That's exactly what thousands of people have found at Backed by experienced surgeons, cutting-edge technology, and personalized care, Capilclinic has become a go-to destination for those seeking results that don't just restore hair, but restore confidence. It's more than a procedure—it's a fresh start, guided by one of the most trusted names in the industry. What Makes Capilclinic the Best? Capilclinic has become a household name for hair transplant solutions—not just in Turkey, but worldwide. Recognized with the 2024 European Award in Hair Surgery, their reputation is built on results that genuinely resemble natural hair, not surgery. And it's not just one lucky patient or two—this is consistent, high-quality care that has worked for thousands of patients. Here's what makes them different: ● Their Min Time FUE™ method ensures grafts spend less time outside the body, improving the survival rate. ● They offer 100% natural-looking results by customizing every procedure to your face, hair type, and goals. ● Their packages are transparent, starting from just €2,190 in Turkey—no tricks, no hidden fees or upsells. It's not about hype. It's about patients getting their lives and hair back. The Science Behind the Look: Min Time FUE™ Most clinics in Turkey offer some version of FUE (Follicular Unit Extraction). But Capilclinic uses a proprietary version called Min Time FUE™. Sounds technical, right? Here's what it really means: Your hair follicles are like little seeds. The less time they're out of your scalp, the more likely they are to 'take root' and grow healthy, strong hair. Capilclinic's method focuses on speed and precision, drastically reducing the time follicles spend outside your body during surgery. This means: ● Less trauma to the grafts ● Faster healing ● Better density ● Natural hairlines It's the kind of innovation you'd expect from a clinic recognized with a European medical award. Real Patients. Real Results. There's something powerful about seeing transformation stories. People who once wore hats every day now proudly rock their natural hair. Like Bradley, who was self-conscious about his hairline for years. Or Neil, who said, 'Capilclinic changed my life forever.' Scroll through the it's all there—before and after photos, real people, real results. No filters. No false promises. Beyond Transplants: PRP and Mesotherapy Support Hair transplants aren't the whole story. To make sure the new hair is strong and long-lasting, Capilclinic also includes: ● PRP (Platelet-Rich Plasma): Uses your own blood's healing powers to strengthen hair roots ● Mesotherapy: Nourishes the scalp with essential nutrients These treatments are gentle, non-invasive, and often included as part of the package. Award-Winning Care Backed by Experience In 2024, Capilclinic received the European Award in Hair Surgery, a testament to its trustworthiness within the medical industry. That recognition isn't easy to earn—it's proof of clinical excellence, innovation, and satisfied patients. They're not some pop-up clinic. Capilclinic has medical teams in Turkey, the UK, Spain, France, Mexico, and Colombia, and they've treated over 20,000 patients worldwide. Their head surgeon, Dr. Oguz Kayiran, is internationally recognized and brings over a decade of experience to each procedure. Transparent Pricing That Makes Sense Let's talk about cost—because it matters. Capilclinic offers all-inclusive packages starting at: ● €2,190 in Turkey ● £3,500 in the UK That includes the surgery, hotel stay, transfers, aftercare, and additional treatments. There are no surprise charges when you arrive. It's all upfront. And most importantly, you're paying for value, not just a procedure. The Process: What to Expect Capilclinic makes things simple: 1 . Free Online Assessment: You send photos of your scalp and get a custom evaluation—no charge. 2 . Pre-Procedure Planning: You speak with the medical team (and translator, if needed) to map out your surgery. 3 . Surgery Day: Local anesthesia, extraction, and implantation—carried out by specialists using sapphire tools. 4 . Aftercare and Results: Detailed post-op care, PRP sessions, and follow-ups ensure you heal comfortably. It's not just a service—it's a guided journey with full support. Why Hair Transplant in Turkey? Why Capilclinic? Turkey is known for being a global hub for medical tourism, especially in cosmetic surgery. But not all clinics are created equal. What makes Capilclinic stand out among the best hair transplant clinics in Turkey is their: ● Hospital-grade facilities ● European-trained doctors ● On-site translators ● Lifetime warranty on transplants They've taken all the uncertainty out of the process so you can focus on results. Still Wondering If It's Right for You? If you're unsure whether this is the right move, start a free, no-obligation assessment to review your hair loss pattern, scalp health, and goals. You'll receive honest advice from medical professionals who understand that this is a big, personal decision. No pressure. No upselling. Just guidance tailored to your situation. Their team walks you through every step—from planning to aftercare—with clarity and empathy. You'll know exactly what to expect, how the process works, and what kind of results are realistic. This isn't about selling dreams. It's about delivering the best hair transplant in Turkey with genuine care and trusted expertise. You've waited long enough. Now you've found the clinic that's ready to help. Conclusion Choosing to undergo a hair transplant is more than just a cosmetic decision—it's personal. It's about feeling like yourself again. That's why picking the best hair transplant clinic in Turkey really matters. With Capilclinic, you're not just choosing advanced medical care; you're choosing people who care about your journey. From consultation to recovery, every step is transparent, professional, and focused on your comfort and satisfaction. With their exclusive Min Time FUE™, natural results, and global recognition, Capilclinic offers more than just hair restoration—they offer renewed confidence. Whether you've just started researching or are
